Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors

US8541444B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Jun Li · Foster City, US
• Jeffrey A. Robl · Newtown, US
• James J. Li · Pennington, US
• Lawrence J. Kennedy · Titusville, US
• Haixia Wang · San Diego, US
• Jie Li · Shanghai, CN
• Chenkou Wei · Princeton Junction, US
• Michael Galella · Kendall Park, US

Key dates

• Filing date: Aug 3, 2011
• Grant date: Sep 24, 2013
• Expiry date: Sep 21, 2031

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I:or stereoisomers or pharmaceutically acceptable salts thereof, wherein G, Q, X, Y, R3, R3a, and R3b are defined herein.